| Zacks Company Profile for Xencor, Inc. (XNCR : NSDQ) |
|
|
| |
| • Company Description |
| Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.
Number of Employees: 250 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $15.31 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 691,848 shares |
| Shares Outstanding: 71.41 (millions) |
| Market Capitalization: $1,093.29 (millions) |
| Beta: 0.97 |
| 52 Week High: $24.66 |
| 52 Week Low: $6.92 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-15.60% |
-15.46% |
| 12 Week |
17.23% |
15.34% |
| Year To Date |
0.00% |
0.00% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
465 NORTH HALSTEAD STREET SUITE 200
-
PASADENA,CA 91107
USA |
ph: 626-305-5900
fax: 626-305-0350 |
investors@xencor.com |
http://www.xencor.com |
|
|
| |
| • General Corporate Information |
Officers
Bassil I. Dahiyat - Chief Executive Officer; President and Director
Bart Jan Cornelissen - Sr. Vice President & Chief Financial Officer
A. Bruce Montgomery - Director
Kurt Gustafson - Director
Kevin C. Gorman - Director
|
|
Peer Information
Xencor, Inc. (GSAC)
Xencor, Inc. (CASI)
Xencor, Inc. (ALCD.)
Xencor, Inc. (OMNN)
Xencor, Inc. (CGPI.)
Xencor, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 98401F105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/26/26
|
|
Share - Related Items
Shares Outstanding: 71.41
Most Recent Split Date: (:1)
Beta: 0.97
Market Capitalization: $1,093.29 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.67 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.71 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 10.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 53.07% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 02/26/26 |
|
|
|
| |
